UK markets closed

Edwards Lifesciences Corporation (EW)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
69.28-0.68 (-0.97%)
At close: 04:00PM EDT
69.28 0.00 (0.00%)
After hours: 06:06PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 42.12B
Enterprise value 41.29B
Trailing P/E 30.65
Forward P/E 24.63
PEG ratio (5-yr expected) 4.08
Price/sales (ttm)7.54
Price/book (mrq)6.61
Enterprise value/revenue 7.30
Enterprise value/EBITDA 21.49

Trading information

Stock price history

Beta (5Y monthly) 1.03
52-week change 3-18.93%
S&P500 52-week change 316.57%
52-week high 394.87
52-week low 367.13
50-day moving average 377.34
200-day moving average 381.45

Share statistics

Avg vol (3-month) 33.31M
Avg vol (10-day) 33.56M
Shares outstanding 5607.92M
Implied shares outstanding 6607.92M
Float 8602.29M
% held by insiders 10.85%
% held by institutions 185.59%
Shares short (14 Sept 2023) 412.7M
Short ratio (14 Sept 2023) 43.91
Short % of float (14 Sept 2023) 42.11%
Short % of shares outstanding (14 Sept 2023) 42.09%
Shares short (prior month 14 Aug 2023) 49.51M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 23:1
Last split date 331 May 2020

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2022
Most-recent quarter (mrq)29 Jun 2023


Profit margin 24.56%
Operating margin (ttm)28.44%

Management effectiveness

Return on assets (ttm)11.54%
Return on equity (ttm)22.40%

Income statement

Revenue (ttm)5.66B
Revenue per share (ttm)9.25
Quarterly revenue growth (yoy)11.40%
Gross profit (ttm)4.3B
Net income avi to common (ttm)1.39B
Diluted EPS (ttm)2.23
Quarterly earnings growth (yoy)-24.40%

Balance sheet

Total cash (mrq)1.51B
Total cash per share (mrq)2.48
Total debt (mrq)684.5M
Total debt/equity (mrq)10.62%
Current ratio (mrq)3.15
Book value per share (mrq)10.49

Cash flow statement

Operating cash flow (ttm)940.4M
Levered free cash flow (ttm)808.52M